Abstract
Cancer cells create a microenvironment that prevents tumor rejection by the host’s immune system. The activation of pattern recognition receptors (PRRs) can elicit an innate immune response and guide the adaptive immune response to overcome this. dsRNA analogs can trigger TLR3, RIG-I, MDA5, NLRP3 and several other PRRs to induce not only robust immune response against cancer but also programmed cell death. This review focuses on the signal pathways activated by dsRNA and examines examples of their clinical application in cancer treatment.
Keywords: Adjuvant, cancer vaccine, cross-presentation, cytokine, cytotoxic T lymphocyte, dendritic cell, double-stranded RNA, inflammasome, immune response, immunoediting, immunotherapy, melanoma differentiation-associated gene 5, nucleotide-binding domain and leucine-rich repeat containing gene family pyrin domain 3, polyadenylic-polyuridylic acid, polyinosinic-polycytidylic acid, poly (I:C12U), poly (ICLC), retinoic acid-inducible gene-I, T helper cell, toll-like receptor, tumor, tumor associated antigen.
Anti-Cancer Agents in Medicinal Chemistry
Title:Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Volume: 14 Issue: 2
Author(s): Bo Jin, Liu-Fang Cheng, Kai Wu, Xiao-Hong Yu and Anthony E.T. Yeo
Affiliation:
Keywords: Adjuvant, cancer vaccine, cross-presentation, cytokine, cytotoxic T lymphocyte, dendritic cell, double-stranded RNA, inflammasome, immune response, immunoediting, immunotherapy, melanoma differentiation-associated gene 5, nucleotide-binding domain and leucine-rich repeat containing gene family pyrin domain 3, polyadenylic-polyuridylic acid, polyinosinic-polycytidylic acid, poly (I:C12U), poly (ICLC), retinoic acid-inducible gene-I, T helper cell, toll-like receptor, tumor, tumor associated antigen.
Abstract: Cancer cells create a microenvironment that prevents tumor rejection by the host’s immune system. The activation of pattern recognition receptors (PRRs) can elicit an innate immune response and guide the adaptive immune response to overcome this. dsRNA analogs can trigger TLR3, RIG-I, MDA5, NLRP3 and several other PRRs to induce not only robust immune response against cancer but also programmed cell death. This review focuses on the signal pathways activated by dsRNA and examines examples of their clinical application in cancer treatment.
Export Options
About this article
Cite this article as:
Jin Bo, Cheng Liu-Fang, Wu Kai, Yu Xiao-Hong and Yeo E.T. Anthony, Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/18715206113136660373
DOI https://dx.doi.org/10.2174/18715206113136660373 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Cell Cannibalism: A Primeval Option to Survive.
Current Molecular Medicine 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention
Current Drug Targets Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer
Current Drug Targets Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies Recurrent Left Atrial Low-grade Malignant Inflammatory Myofibroblastic Tumor Characterized by Cardiovascular Magnetic Resonance
Current Medical Imaging The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Antimicrobial Activity of Willowherb (Epilobium angustifolium L.) Leaves and Flowers
Current Drug Targets EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy NAD+-Linked 15-Hydroxyprostaglandin Dehydrogenase: Structure and Biological Functions
Current Pharmaceutical Design Intestinal Immunomodulation. Role of Regulative Peptides and Promising Pharmacological Activities
Current Pharmaceutical Design Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Inhibitors of the Hedgehog Signal Transduction Pathway
Current Cancer Therapy Reviews HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Inflammatory Network
Inflammation & Allergy - Drug Targets (Discontinued) Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism